Gene:
EPHX1
epoxide hydrolase 1, microsomal (xenobiotic)

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for EPHX1

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1051740 NC_000001.10:g.226019633T>C, NC_000001.11:g.225831932T>C, NG_009776.1:g.26837T>C, NM_000120.3:c.337T>C, NM_001136018.3:c.337T>C, NM_001291163.1:c.337T>C, NP_000111.1:p.Tyr113His, NP_001129490.1:p.Tyr113His, NP_001278092.1:p.Tyr113His, XM_005273085.1:c.337T>C, XP_005273142.1:p.Tyr113His, rs16845366, rs17417482, rs1800444, rs2259405, rs3192120, rs52794507, rs59266540
T > C
SNP
Y113H
No VIP available No Clinical Annotations available VA
rs1051741 NC_000001.10:g.226032229C>T, NC_000001.11:g.225844528C>T, NG_009776.1:g.39433C>T, NM_000120.3:c.1071C>T, NM_001136018.3:c.1071C>T, NM_001291163.1:c.1071C>T, NP_000111.1:p.Asn357=, NP_001129490.1:p.Asn357=, NP_001278092.1:p.Asn357=, XM_005273085.1:c.1071C>T, XP_005273142.1:p.Asn357=, XR_949163.1:n.2830+2310G>A, rs2292569, rs3192122, rs56555531, rs60193447
C > T
SNP
N357N
No VIP available CA VA
rs1131873 NC_000001.10:g.226019653G>A, NC_000001.11:g.225831952G>A, NG_009776.1:g.26857G>A, NM_000120.3:c.357G>A, NM_001136018.3:c.357G>A, NM_001291163.1:c.357G>A, NP_000111.1:p.Lys119=, NP_001129490.1:p.Lys119=, NP_001278092.1:p.Lys119=, XM_005273085.1:c.357G>A, XP_005273142.1:p.Lys119=, rs11540968, rs17417489, rs2292566, rs3192121, rs386563972, rs59577327
G > A
SNP
K119K
No VIP available CA VA
rs1877724 NC_000001.10:g.226013355C>T, NC_000001.11:g.225825654C>T, NG_009776.1:g.20559C>T, NM_000120.3:c.-6+110C>T, NM_001136018.3:c.-5-3071C>T, NM_001291163.1:c.-5-3071C>T, XM_005273085.1:c.-5-3071C>T, rs2854454, rs3738041, rs57352464
C > T
SNP
No VIP available CA VA
rs2234922 NC_000001.10:g.226026406A>G, NC_000001.11:g.225838705A>G, NG_009776.1:g.33610A>G, NM_000120.3:c.416A>G, NM_001136018.3:c.416A>G, NM_001291163.1:c.416A>G, NP_000111.1:p.His139Arg, NP_001129490.1:p.His139Arg, NP_001278092.1:p.His139Arg, XM_005273085.1:c.416A>G, XP_005273142.1:p.His139Arg, rs59975602
A > G
SNP
H139R
No VIP available No Clinical Annotations available VA
rs2260863 NC_000001.10:g.226019774G>C, NC_000001.11:g.225832073G>C, NG_009776.1:g.26978G>C, NM_000120.3:c.364+114G>C, NM_001136018.3:c.364+114G>C, NM_001291163.1:c.364+114G>C, XM_005273085.1:c.364+114G>C, rs57978216
G > C
SNP
No VIP available No Clinical Annotations available VA
rs3738046 NC_000001.10:g.226016558G>C, NC_000001.11:g.225828857G>C, NG_009776.1:g.23762G>C, NM_000120.3:c.128G>C, NM_001136018.3:c.128G>C, NM_001291163.1:c.128G>C, NP_000111.1:p.Arg43Thr, NP_001129490.1:p.Arg43Thr, NP_001278092.1:p.Arg43Thr, XM_005273085.1:c.128G>C, XP_005273142.1:p.Arg43Thr, rs386467447, rs60900310
G > C
SNP
R43T
No VIP available No Clinical Annotations available VA
rs4653436 NC_000001.10:g.225995211G>A, NC_000001.11:g.225807509G>A, NG_009776.1:g.2415G>A, rs57171465
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  EPHX
Alternate Symbols:  None
PharmGKB Accession Id: PA27829

Details

Cytogenetic Location: chr1 : q42.12 - q42.12
GP mRNA Boundary: chr1 : 225997797 - 226033264
GP Gene Boundary: chr1 : 225987797 - 226036264
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Warfarin Pathway, Pharmacodynamics
    Simplified diagram of the target of warfarin action and downstream genes and effects.
No related genes are available

Curated Information ?

Curated Information ?

Publications related to EPHX1: 40

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. Medicine. 2017. Liu Rui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. Pharmacogenomics. 2016. Fricke-Galindo Ingrid, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes. International journal of chronic obstructive pulmonary disease. 2015. Zhang Jian-Qing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy. Pharmacogenomics. 2015. Ma Chun-Lai, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients. PloS one. 2015. Daci Armond, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics. 2014. Khrunin Andrey V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014. Zhu Xu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A pharmacogenetics-based warfarin maintenance dosing algorithm from northern chinese patients. PloS one. 2014. Chen Jinxing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. de Graan Anne-Joy M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population. Basic & clinical pharmacology & toxicology. 2013. Ozer Mahmut, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013. Puranik Yogita Ghodke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: phenytoin pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. British journal of clinical pharmacology. 2012. Lacut Karine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics. 2012. Ramirez Andrea H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
EPHX1 Polymorphisms Are Not Associated With Warfarin Response in an Italian Population. Clinical pharmacology and therapeutics. 2011. Ciccacci C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. European journal of clinical pharmacology. 2011. Geisen Christof, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of drug-induced birth defects: what is known so far?. Pharmacogenomics. 2011. Wilffert Bob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic warfarin dosing tables versus algorithms. Journal of the American College of Cardiology. 2011. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population. Pharmacogenetics and genomics. 2011. Chan Sze Ling, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thrombosis and haemostasis. 2011. Luxembourg Baete, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. The Journal of molecular diagnostics : JMD. 2010. Pratt Victoria M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
New genetic variant that might improve warfarin dose prediction in African Americans. British journal of clinical pharmacology. 2010. Schelleman Hedi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clinical pharmacology and therapeutics. 2010. Pautas E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations. Pharmacogenetics and genomics. 2010. Azzato Elizabeth M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics. 2009. Lee M T Michael, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clinical neuropharmacology. 2009. Makmor-Bakry Mohd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Chronic obstructive pulmonary disease: towards pharmacogenetics. Genome medicine. 2009. Wood Alice M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and benzene metabolism in humans exposed to a wide range of air concentrations. Pharmacogenetics and genomics. 2007. Kim Sungkyoon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of warfarin dose with genes involved in its action and metabolism. Human genetics. 2007. Wadelius Mia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thrombosis and haemostasis. 2006. Vecsler Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology (Cambridge, Mass.). 2006. Kiyohara Chikako, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clinical pharmacology and therapeutics. 2005. Loebstein Ronen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. European journal of clinical pharmacology. 2005. Nakajima Yukiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are associated with polycystic ovary syndrome. Fertility and sterility. 2003. Korhonen Seija, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase?. Therapeutic drug monitoring. 1995. Svinarov D A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prenatal prediction of risk of the fetal hydantoin syndrome. The New England journal of medicine. 1990. Buehler B A, et al. PubMed

LinkOuts

NCBI Gene:
2052
OMIM:
132810
189800
UCSC Genome Browser:
NM_000120
RefSeq RNA:
NM_000120
NM_001136018
RefSeq Protein:
NP_000111
NP_001129490
RefSeq DNA:
NG_009776
NT_167186
UniProtKB:
B2R8N0_HUMAN (B2R8N0)
HYEP_HUMAN (P07099)
Ensembl:
ENSG00000143819
GenAtlas:
EPHX1
GeneCard:
EPHX1
MutDB:
EPHX1
ALFRED:
LO000306J
HuGE:
EPHX1
Comparative Toxicogenomics Database:
2052
ModBase:
Q9NQV0
HumanCyc Gene:
HS07112
HGNC:
3401

Common Searches